Cargando…
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target
Uveal melanoma is a rare form of melanoma with particularly poor outcomes in the metastatic setting. In contrast with cutaneous melanoma, uveal melanoma lacks BRAF mutations and demonstrates very low response rates to immune-checkpoint blockade. Our objectives were to study the transcriptomics of me...
Autores principales: | Bao, Riyue, Surriga, Oliver, Olson, Daniel J., Allred, Jacob B., Strand, Carrie A., Zha, Yuanyuan, Carll, Timothy, Labadie, Brian W., Bastos, Bruno R., Butler, Marcus, Hogg, David, Musi, Elgilda, Ambrosini, Grazia, Munster, Pamela, Schwartz, Gary K., Luke, Jason J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755667/ https://www.ncbi.nlm.nih.gov/pubmed/33170593 http://dx.doi.org/10.1097/CMR.0000000000000701 |
Ejemplares similares
-
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
por: Ambrosini, Grazia, et al.
Publicado: (2015) -
The GPER Agonist LNS8801 Induces Mitotic Arrest and Apoptosis in Uveal Melanoma Cells
por: Ambrosini, Grazia, et al.
Publicado: (2023) -
Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype
por: Ho, Alan L., et al.
Publicado: (2012) -
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2021) -
Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
por: Musi, Elgilda, et al.
Publicado: (2019)